Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00278174|
Recruitment Status : Completed
First Posted : January 18, 2006
Last Update Posted : May 4, 2011
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer.
PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Biological: recombinant interferon alpha-1b||Phase 2|
- Determine the objective response rate in patients with metastatic renal clear cell carcinoma treated with interferon alfa-1b.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278174
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44195|
|Study Chair:||Ronald M. Bukowski, MD||The Cleveland Clinic|